Related Experiment Videos
Development of anticancer drugs targeting the MAP kinase pathway
1Pfizer Global Research and Development, Ann Arbor Laboratories, Michigan 48105, USA.
Abstract:
Since the discovery of the role of ras oncogenes in tumorigenesis, we have witnessed an explosion of research in the signal transduction area. In the quest to understand how Ras transmits extracellular growth signals, the MAP kinase (MAPK) pathway has emerged as the crucial route between membrane-bound Ras and the nucleus. The MAPK pathway encompasses a cascade of phosphorylation events involving three key kinases, namely Raf, MEK (MAP kinase kinase) and ERK (MAP kinase). This kinase cascade presents novel opportunities for the development of new cancer therapies designed to be less toxic than conventional chemotherapeutic drugs. Furthermore, as a signal transduction-based approach to cancer treatment, inhibition of any one of these targets has the potential for translational pharmacodynamic evaluation of target suppression. The rationale for targeting the MAP kinase pathway will be reviewed here along with a discussion of various pharmacological approaches and the promise they hold for a new generation of anticancer drugs.
Insights
The MAP kinase (MAPK) pathway, crucial for transmitting growth signals, offers new, less toxic cancer therapy opportunities. Targeting this pathway allows for pharmacodynamic evaluation of drug effectiveness against cancer.
Area of Science:
- Oncology
- Molecular Biology
- Signal Transduction
Background:
- Ras oncogenes play a key role in tumorigenesis.
- The MAP kinase (MAPK) pathway is a critical signaling cascade transmitting extracellular growth signals from membrane-bound Ras to the nucleus.
- This pathway involves a series of phosphorylation events mediated by Raf, MEK (MAP kinase kinase), and ERK (MAP kinase).
Purpose of the Study:
- To review the rationale for targeting the MAP kinase pathway in cancer therapy.
- To discuss various pharmacological approaches for inhibiting the MAPK pathway.
- To explore the potential of MAPK pathway inhibitors as a new generation of anticancer drugs.
Main Methods:
- Review of existing literature on Ras oncogenes and the MAPK pathway.
- Analysis of the MAPK pathway's components (Raf, MEK, ERK) as therapeutic targets.
- Discussion of pharmacological strategies for pathway inhibition.
Main Results:
- The MAPK pathway is a central mediator of growth signals relevant to cancer.
- Inhibiting components of the MAPK pathway presents a promising strategy for cancer treatment.
- Targeting this pathway allows for translational pharmacodynamic evaluation.
Conclusions:
- The MAPK pathway is a validated target for novel anticancer drug development.
- Pharmacological inhibition of the MAPK pathway holds promise for less toxic cancer therapies.
- This signal transduction-based approach offers a new generation of targeted cancer treatments.